Company Outline

Our Business Model

Our pharmaceutical business comprises the in-licensing drug candidates, developed on technologies pioneered by Kagoshima University, under licensing agreements or joint research agreements, and the primarily in-house nonclinical studies and early-stage clinical development of these drug candidates.

After establishing proof-of-concept (POC) (i.e., demonstrating an investigational drug’s efficacy when administered to patients) of our drug candidates as an initial indicator of their commercial value, we will build a revenue model consisting of lump-sum and milestone payments and post-marketing royalty payments through out-licensing to major pharmaceutical companies. These pharmas will then conduct Phase III (P3) studies typically on a cost scale of several tens of billion yen, and will subsequently market the approved drug products.

Through these business activities, Surv BioPharma will create a business structure with sustained and stable profitability, and will contribute to delivering the innovative seed technologies pioneered by Kagoshima University to society.

We will fulfill our corporate social responsibility as a drug discovery venture company originating from Kagoshima University by delivering new therapeutic drugs to patients via major pharmaceutical companies.